Mapracorat Ophthalmic Suspension, 3% for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The objective of this clinical study is to compare the safety and efficacy of mapracorat
ophthalmic suspension, 3% with its vehicle for the treatment of postoperative inflammation
and pain following cataract surgery.